Amphiphilic peptide carrier for the combined delivery of curcumin and plasmid DNA into the lungs

Park, Ji Hwan; Kim, Hyun Ah; Park, Jin Hyeong; Lee, Minhyung

doi:10.1016/j.biomaterials.2012.05.046

Cited by 45 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, due to its low-charge density, R3V6 was not toxic to cells [23,24]. Another significant advantage of R3V6 is that it forms micelle structures in aqueous solution; therefore, hydrophobic drugs such as dexamethasone and curcumin can be loaded into the cores of R3V6 peptide micelles [26]. Therefore, R3V6 may be a useful carrier for drug and gene combination therapies.…”

Section: Introductionmentioning

confidence: 99%

Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy

Song

Choi

et al. 2015

Journal of Drug Targeting

Self Cite

View full text Add to dashboard Cite

Inhibition of microRNA-21 (miR-21) has been shown to promote apoptosis of cancer cells and to reduce tumor size in glioblastoma. However, efficient carriers for antisense-oligodeoxynucleotide (antisense-ODN) against miR-21 have not yet been developed. In this study, the R3V6 peptide (R3V6) was evaluated as a carrier of antisense-ODN. In a gel retardation assay, R3V6 formed a complex with an antisense-ODN. The serum stability assay showed that R3V6 protected it from nucleases more efficiently than polyethylenimine (PEI; 25 kDa, PEI25k). A Renilla luciferase gene with a 3'-untranslated region (3'-UTR) recognizable by miR-21 (psiCHECK2-miR-21-UTR) was constructed for the antisense-ODN assay. psiCHECK2-miR-21-UTR expressed less Renilla luciferase in the cells with a higher level of miR-21 due to the effect of miR-21. In an in vitro transfection assay, the R3V6 peptide delivered anti-miR-21 antisense-ODN into cells more efficiently than PEI (25 kDa, PEI25k) and lipofectamine. As a result, antisense-ODN/R3V6 complex inhibited miR-21 and increased Renilla luciferase expression more efficiently than antisense-ODN/PEI25k or antisense-ODN/Lipofectamine complexes in both C6 and A172 glioblastoma cells. Furthermore, the antisense-ODN/R3V6 complexes reduced the level of miR-21 and induced apoptosis of glioblastoma cells. These results suggest that the R3V6 peptide may be a useful carrier of antisense-ODN for glioblastoma gene therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy

Song

Choi

et al. 2015

Journal of Drug Targeting

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, R7L10-curcumin more effectively reduced the TNF-a level in lipopolysaccharide-activated Raw264.7 macrophage cells than CUR only [166]. The in-vivo results showed that R7L10-curcumin delivered pDNA with better efficiency and reduced the TNF-a level in lung tissues in an acute lung injury mouse model [166]. Similarly, to assess the effect of combination therapy, CUR was delivered along with herpes simplex virus thymidine kinase (HSVtk) gene using R7L10 peptide micelles as a carrier in glioblastoma animal model [167].…”

Section: Polymeric Micellesmentioning

confidence: 89%

“…The intracellular CUR delivery efficiency was found to be higher for of R7L10-CUR than CUR alone. Moreover, R7L10-curcumin more effectively reduced the TNF-a level in lipopolysaccharide-activated Raw264.7 macrophage cells than CUR only [166]. The in-vivo results showed that R7L10-curcumin delivered pDNA with better efficiency and reduced the TNF-a level in lung tissues in an acute lung injury mouse model [166].…”

Section: Polymeric Micellesmentioning

confidence: 96%

“…In another finding, Huang et al [165] encapsulated the CUR into phosphatidylcholine-shielding micelles and exhibited the improve cellular uptake by HeLa cells [165]. However, Park et al [166] assessed the amphiphilic R7L10 peptide carrier for the combined delivery of CUR and plasmid DNA into lungs. In-vitro transfection study demonstrated the greater transfection efficiency of R7L10-CUR relative to R7L10 [166].…”

Section: Polymeric Micellesmentioning

confidence: 99%

“…However, Park et al [166] assessed the amphiphilic R7L10 peptide carrier for the combined delivery of CUR and plasmid DNA into lungs. In-vitro transfection study demonstrated the greater transfection efficiency of R7L10-CUR relative to R7L10 [166]. The intracellular CUR delivery efficiency was found to be higher for of R7L10-CUR than CUR alone.…”

Section: Polymeric Micellesmentioning

confidence: 99%

See 2 more Smart Citations

Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art

Ahmad

Alkahtani

Akhter

et al. 2015

Journal of Drug Targeting

View full text Add to dashboard Cite

Comprehensive pharmacological screening of curcumin (CUR) has given the evidence that it is an excellent naturally occurring therapeutic moiety for cancer. It is very well tolerated with insignificant toxicity even after high doses of oral administration. Irrespective of its better quality as an anticancer agent, therapeutic application of CUR is hampered by its extremely low-aqueous solubility and poor bioavailability, rapid clearance and low-cellular uptake. A simple means of breaking up the restrictive factor of CUR is to perk-up its aqueous solubility, improve its bioavailability, protect it from degradation, and metabolism and potentiate its targeting capacity towards the cancer cell. The development in the field of nanomedicine has made excellent progresses toward enhancing the bioavailability of lipophilic drugs like CUR. Nanoparticles (NPs) are capable to deliver the CUR at specific area and thereby prevent it from physiological degradation and systemic clearance. In recent year, an assortment of nanomedicine-based novel drug delivery system has been designed to potentiate the bioavailability of CUR towards anticancer therapy. In this review, we discuss the recent development in the field of nanoCUR (NanoCur), including polymeric micelles, liposome, polymeric NPs, nanoemulsion, nanosuspension, solid lipid NPs (SLNPs), polymer conjugates, nanogel, etc. in anticancer application.

show abstract

An mTOR siRNA‐Loaded Spermidine/DNA Tetrahedron Nanoplatform with a Synergistic Anti‐Inflammatory Effect on Acute Lung Injury

Huang

You

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

Acute lung injury (ALI) is characterized by severe inflammation and damage to the lung air–blood barrier, resulting in respiratory function damage and life‐threatening outcomes. Macrophage polarization plays an essential role in the occurrence, development, and outcome of ALI. As drug carriers, self‐assembled DNA nanostructures can potentially overcome the drawbacks and limitations of traditional anti‐inflammatory agents owing to their nontoxicity, programmability, and excellent structural control at the nanoscale. A small interfering RNA (siRNA) and drug dual therapy nanoplatform are proposed and constructed here to combat ALI. The nanoplatform consists of a spermidine‐assembled DNA tetrahedron and four mammalian target of rapamycin siRNAs. Spermidine serves as a mediator of drug delivery vehicle synthesis and a drug that alters macrophage polarization. Both spermidine and siRNA exert anti‐inflammatory effects in vitro and in vivo by regulating the macrophage phenotype. More importantly, these factors exhibit a synergistic anti‐inflammatory effect by promoting macrophage autophagy. For the first time, an anti‐inflammatory dual therapy strategy that uses self‐assembled DNA nanostructures as nontoxic, programmable delivery vehicles is proposed and demonstrated through this work. Future work on utilizing DNA nanostructures for the treatment of noncancerous diseases such as ALI is highly promising and desirable.

show abstract

Amphiphilic peptide carrier for the combined delivery of curcumin and plasmid DNA into the lungs

Cited by 45 publications

References 30 publications

Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy

Delivery of anti-microRNA-21 antisense-oligodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy

Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art

An mTOR siRNA‐Loaded Spermidine/DNA Tetrahedron Nanoplatform with a Synergistic Anti‐Inflammatory Effect on Acute Lung Injury

Contact Info

Product

Resources

About